MassBio CEO & President Kendalle Burlin O’Connell initially posted this update on LinkedIn.
It’s a consequential week in federal health policy. SBIR funding is finally back. FDA uncertainty is getting worse. And Capitol Hill is about to give the life sciences industry an extended look at where the Administration’s priorities are headed. Here’s what we’re tracking:
SBIR Reauthorization Restores Critical Funding: On April 13, after more than six months of disruption, President Trump signed the Small Business Innovation and Economic Security Act into law, reauthorizing the SBIR and STTR programs through September 30, 2031. For Massachusetts biotech companies, among the country’s leading recipients of these awards, the lapse froze hiring decisions, delayed timelines, and created uncertainty for firms that depend on federal innovation funding as a bridge to private investment. We’re encouraged to see the programs restored and look forward to working with NIH and other agencies to hit the ground running with funding opportunities.
FDA Regulatory Uncertainty Deepens: Replimune announced this week it will cut jobs and substantially scale back its U.S. manufacturing operations following a second Complete Response Letter (CRL) for its melanoma drug, dropping shares 70%. In 2021, the FDA had granted Accelerated Approval for the treatment, but reversed course in the CRL, citing the study as inadequate to support approval. The announcement follows last week’s news that Kezar Life Sciences was forced into a sale after the FDA canceled a scheduled trial design meeting without explanation, delaying it four months and collapsing the company’s financing timeline. For small biotechs operating on limited runways, the agency’s unpredictability, including staff turnover and shifting positions on key regulatory questions, is creating real challenges. If your company is facing difficulties due to agency unpredictability, reach out as we bring these examples to the Hill.
HHS Secretary RFK Jr. on the Hill: HHS Secretary Robert F. Kennedy Jr. will testify before multiple committees this week, beginning Thursday April 16th with back-to-back appearances before House Ways and Means and House Appropriations, followed by House Education and Workforce on Friday April 17th. The following week, Secretary Kennedy will appear before House Energy and Commerce and Senate Appropriations on Tuesday, April 21, then Senate HELP and Finance on Wednesday, April 22. The hearings will provide an extended opportunity for members to question Kennedy on the Administration’s health policy priorities, budget proposals, and regulatory direction. We will be monitoring these hearings closely for information on how the Administration’s approach to drug pricing, public health, and biomedical innovation may evolve and what implications they carry for the Massachusetts ecosystem.
Senate HELP Hearing on Drug Pricing and Chairman Cassidy’s MVP Agenda: Senate HELP is holding a Hearing today, Thursday, April 16, “Making Medicines More Affordable: How Competition Can Lower Drug Prices,” where Chairman Cassidy will unveil his Money and Value for Patients (MVP) agenda. The agenda proposes giving money directly to patients to cover out-of-pocket costs, empowering price transparency to drive competition, and addressing unhealthy foods as part of a broader effort to make health care more affordable. While we share the goal of making medicines accessible, we will be watching to ensure any proposals do not inadvertently undermine the incentives that drive investment in early-stage drug development in Massachusetts and across the country.
House Subcommittee Hearing on PBM Business Model: The House Education and Workforce Subcommittee on Health, Employment, Labor, and Pensions will hold a hearing on Wednesday, April 22, “Profits Over Patients: The PBM Business Model Under Scrutiny,” examining pharmacy benefit manager practices and their impact on drug pricing and patient access. MassBio believes meaningful PBM reforms can lower drug prices without sacrificing innovation and we will be monitoring the hearing closely.